

Hypertension in adults (update) Committee meeting

Date: 28/02/2018

Location: NGC Boardroom, Royal College of Physicians, 11 St Andrew's Place, London NW1 4LE

Minutes: Confirmed

NICE National Institute for Health and Care Excellence

Committee members present:		
Anthony Wierzbicki (Chair)		(Present for notes 1–5)
Liz Clark		(Present for notes 1–5)
Elizabeth Denver		(Present for notes 1–5)
Mark Glover		(Present for notes 1–5)
Judith Magowan		(Present for notes 1–5)
Terry McCormack		(Present for notes 1–5)
Irene McGill		(Present for notes 1–5)
Richard McManus		(Present for notes 1–5)
Lucy Pollock		(Present for notes 1–5)
Mark Shapley		(Present for notes 1–5)
Bryan Williams		(Present for notes 1–5)

In attendance:		
Caroline Kier	Guideline Commissioning Manager, NICE	(Present for notes 1–5 via telephone)
Jane Lynn	Business Analyst, NICE	(Present for notes 1–5)
Rebecca Boffa	Research Fellow, NGC	(Present for notes 1–5)
Serena Carville	Guideline Lead, NGC	(Present for notes 1–5)
Margaret Constanti	Senior Health Economist, NGC	(Present for notes 1–5)
Meredith Faust	Project Manager, NGC	(Present for notes 1–5)
Christopher Floyd	Clinical Trainee, NGC	(Present for notes 1–5)
Qudsia Malik	Senior Research Fellow, NGC	(Present for notes 1–5)

Apologies:

Alison Warren	Committee member
Catherine Baden-Daintree	Senior Medical Editor, NICE
Beatriz Ferrer-Quiles	Information Specialist, NGC

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the fifth meeting on Hypertension in adults.

No members of the public asked to observe the meeting.

The Chair informed the committee that apologies had been received. These are noted above.

The Chair outlined the objectives of the meeting, which included anti-hypertensive drug treatments, economics of diagnostic model update, targets to improve outcomes and finalising protocols for sequencing.

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was anti-hypertensive drug treatments, economics of diagnostic model update, targets to improve outcomes and second-, third- and fourth-line sequencing.

The Chair asked everyone to declare verbally any interests that have arisen since the last meeting.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Terry McCormack	Honorary Reader in Primary Care Medicine, Hull York Medical School; Principal in General Practice, Whitby Practice	I am joining the NICE Perioperative Medicine Guideline Committee.	Non-specific personal non-financial	Declare and participate
Bryan Williams	Chair of Medicine, University College London (UCL; HEFCE-tenured); Director, National	Relypsa – Consultancy / steering committee (personal) designing and	Personal financial non-specific	Declare and participate

	<p>Institute for Health Research (NIHR) University College London Hospitals Biomedical; Research Centre (BRC); Director of Research and Development: University College London Hospitals; Consultant Physician and Hypertension Specialist, University College London Hospitals; NIHR Senior Investigator</p>	<p>overseeing the conduct of a phase 3 trial of a potassium-binding agent in patients treated for resistant hypertension.</p>		
--	---	---	--	--

The Chair and a senior member of the Developer’s team noted that the following members would not participate in a part of the meeting:

- Bryan Williams should withdraw from making recommendations in discussions of the following review questions:
 - 3.1 At what blood pressure and/or cardiovascular disease risk threshold should antihypertensive drug treatment be initiated for adults with hypertension?
 - 3.2 Should targets used for antihypertensive therapy be based on blood pressure, cardiovascular risk or a combination of both?

3. Minutes of last meeting

The Chair asked the committee if it wanted any changes made to the minutes of the last meeting. The committee agreed that the minutes were a true and accurate account of the meeting.

The Chair confirmed that all matters arising had been completed or were in hand.

4. Questions and discussion

- A. Qudsia Malik, Senior Research Fellow at the NGC, presented the clinical evidence for the review question ‘At what blood pressure and/or cardiovascular disease risk threshold should antihypertensive drug treatment

be initiated for adults with hypertension?' The committee asked questions about the clinical evidence.

B. Jane Lynn, Business Analyst at NICE, presented the resource impact for the updated economic model regarding diagnostic recommendations for the previous guideline.

C. Margaret Constanti, Senior Health Economist at the NGC, presented the updated diagnostic economic model from the previous guideline with current costs. The committee discussed both economic models.

D. Rebecca Boffa, Research Fellow at the NGC, presented the clinical evidence for the review question 'Should targets used for antihypertensive therapy be based on blood pressure, cardiovascular risk or a combination of both?' The committee asked questions about the clinical evidence.

E. Qudsia Malik led a discussion on finalising the following protocols:

- 4.2 Second- and third-line sequencing
- 4.3 Fourth-line sequencing

The committee discussed and finalised the protocols.

5. Any other business

None.

Date of next meeting: GC6: 25/04/2018

GC7: 26/04/2018

Location of next meeting: NGC Boardroom, Royal College of Physicians, 11 St Andrew's Place, London NW1 4LE